Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPASIL-ESIDRIX #2 vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Serpasil-Esidrix #2 contains reserpine and hydrochlorothiazide. Reserpine irreversibly inhibits the vesicular monoamine transporter 2 (VMAT2) in the CNS and peripheral sympathetic nerve endings, depleting norepinephrine, dopamine, and serotonin from storage vesicles, leading to reduced sympathetic outflow and antihypertensive effect. Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal renal tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and peripheral vascular resistance.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
1 tablet orally once daily. Each tablet contains 0.25 mg reserpine and 50 mg hydrochlorothiazide.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Reserpine: 50-100 hours (biphasic; terminal phase 11-16 days due to slow release from adrenergic storage sites); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment).
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Reserpine is extensively metabolized in the liver via hydrolysis and conjugation, with metabolites excreted in urine and feces. Hydrochlorothiazide is not metabolized extensively; it is primarily eliminated unchanged by the kidneys.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Reserpine: 60% renal (as metabolites), 40% fecal (as parent drug and metabolites); Hydrochlorothiazide: >95% renal (unchanged) via tubular secretion.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Reserpine: 96% bound to albumin; Hydrochlorothiazide: 40-68% bound to albumin.
~20% bound to albumin; minimal binding to other plasma proteins.
Reserpine: 5-8 L/kg (extensive tissue binding, particularly to adrenergic neurons); Hydrochlorothiazide: 0.83-1.14 L/kg (distributes into extracellular fluid).
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Reserpine: 50-60% (oral, extensive first-pass metabolism); Hydrochlorothiazide: 65-75% (oral, with food decreasing absorption by 10-20%).
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
Contraindicated if GFR < 30 m L/min. For GFR 30-59 m L/min, maximum dose is 1 tablet every other day due to hydrochlorothiazide accumulation.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh A: caution, consider reducing dose. Child-Pugh B: contraindicated due to risk of hepatic coma and reserpine-induced depression. Child-Pugh C: contraindicated.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not recommended for children. Safety and efficacy not established.
Not recommended; inadequate safety data.
Initiate with 0.5 tablet once daily due to increased sensitivity to reserpine (CNS depression) and hydrochlorothiazide (hypotension, electrolyte imbalance). Titrate slowly.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
None
None
Reserpine may cause depression, and should be discontinued if symptoms occur; use with caution in patients with history of depression.,Hydrochlorothiazide may cause electrolyte imbalances (e.g., hypokalemia), dehydration, and increased serum uric acid and glucose.,May cause orthostatic hypotension, especially with alcohol or other antihypertensives.,Renal impairment: monitor renal function.,Hepatic impairment: use with caution as reserpine may precipitate hepatic encephalopathy.,Sulfonamide allergy: hydrochlorothiazide is a sulfonamide derivative; cross-sensitivity may occur.,May require dosage adjustment in renal impairment.,Avoid abrupt discontinuation of reserpine; taper gradually.
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Hypersensitivity to reserpine, hydrochlorothiazide, or sulfonamides.,History of mental depression or suicidal tendencies.,Active peptic ulcer or ulcerative colitis.,Electroconvulsive therapy (ECT) within 7 days.,Anuria or severe renal impairment (e.g., creatinine clearance <30 m L/min).,Pheochromocytoma (reserpine may paradoxically increase blood pressure).
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
High-potassium foods (bananas, oranges, spinach) may increase risk of hyperkalemia if used with potassium-sparing diuretics; however, hydrochlorothiazide is potassium-wasting, so hypokalemia risk exists. Avoid excessive sodium intake (processed foods, salt) as it can reduce antihypertensive effect. Grapefruit juice may interact with reserpine; limit consumption.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
Serpasil (reserpine) is classified as FDA Pregnancy Category C. Reserpine crosses the placenta. First trimester: Limited human data, but animal studies suggest increased risk of skeletal and cardiovascular anomalies. Second and third trimesters: Possible adverse effects including neonatal respiratory depression, bradycardia, hypothermia, and hypotonia. Esidrix (hydrochlorothiazide) is FDA Pregnancy Category B; however, thiazide diuretics may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Use only if clearly needed.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Reserpine is excreted into breast milk; M/P ratio not established. Potential for severe adverse effects in nursing infants including respiratory depression, bradycardia, and hypotonia. Hydrochlorothiazide is excreted in breast milk in low amounts (M/P ratio approximately 0.4-0.5), but may suppress lactation and cause electrolyte disturbances. Avoid breastfeeding during therapy.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
Pregnancy can increase volume of distribution and renal clearance, potentially reducing drug concentrations. No specific dose adjustment studies for Serpasil-Esidrix #2; however, based on components: Hydrochlorothiazide may require increased dose due to enhanced clearance, but use lowest effective dose. Reserpine dosing should be minimized due to fetal risks. Avoid use in pregnancy if possible; alternative antihypertensives recommended.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
Serpasil (reserpine) plus Esidrix (hydrochlorothiazide) #2 is a fixed-dose combination for hypertension. Reserpine depletes catecholamines: monitor for depression, nasal congestion, sedation, and bradycardia. Hydrochlorothiazide: check electrolytes, uric acid, glucose; avoid in anuria. Onset of reserpine action is slow (weeks) but prolonged (weeks after discontinuation). Combination may exacerbate gout and diabetes.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take exactly as prescribed; do not stop suddenly as high blood pressure may worsen.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until effects are known.,Avoid alcohol as it can increase dizziness and drowsiness.,Report symptoms of depression, slow heart rate, severe nasal congestion, or unusual bleeding/bruising.,Use sun protection as hydrochlorothiazide increases sun sensitivity.,Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, excessive thirst.,Inform all healthcare providers you are taking this medication, especially before surgery.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPASIL-ESIDRIX #2 vs ALDORIL D50, answered by our medical review team.
SERPASIL-ESIDRIX #2 is a Antihypertensive Combination that works by Serpasil-Esidrix #2 contains reserpine and hydrochlorothiazide. Reserpine irreversibly inhibits the vesicular monoamine transporter 2 (VMAT2) in the CNS and peripheral sympathetic nerve endings, depleting norepinephrine, dopamine, and serotonin from storage vesicles, leading to reduced sympathetic outflow and antihypertensive effect. Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal renal tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and peripheral vascular resistance.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPASIL-ESIDRIX #2 and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPASIL-ESIDRIX #2 is: 1 tablet orally once daily. Each tablet contains 0.25 mg reserpine and 50 mg hydrochlorothiazide.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPASIL-ESIDRIX #2 and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPASIL-ESIDRIX #2 is classified as Category C. Serpasil (reserpine) is classified as FDA Pregnancy Category C. Reserpine crosses the placenta. First trimester: Limited human data, but animal studies suggest increased risk of sk. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.